SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Noven Pharmaceuticals Inc. (NOVN)

Add NOVN Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 9/30/2016 10:12:55 AM - Followers: 0 - Board type: Free - Posts Today: 0

Noven Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of advanced transdermal drug delivery technologies and prescription transdermal products. The company's prescription transdermal patches are used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), as well as in menopausal hormone therapy. Its products include Daytrana for the treatment of ADHD; Vivelle-Dot, a transdermal estrogen therapy product in the United States, which is marketed under the Estradot brand name outside the U.S.; and CombiPatch, a combination estrogen/progestin transdermal patch, which is marketed under the Estalis brand name outside the U.S. The company's menopausal hormone therapy products comprise Vivelle-Dot/Estradot, an advanced estrogen patch; Vivelle/Menorest/Femiest, an original estrogen patch; and CombiPatch/Estalis, a combination estrogen/progestin patch. It sells its products in the United States, Canada, Japan, and Europe. Noven Pharmaceuticals has collaboration agreements with Shire Pharmaceuticals Group plc; P&G Pharmaceuticals, Inc.; and Endo Pharmaceuticals, Inc. to develop a range of new patches. The company was founded in 1987 and is headquartered in Miami, Florida.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NOVN News: New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product 01:15 AM
NOVN News: Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL 12/03/2016 07:00:36 PM
NOVN News: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study 12/03/2016 01:00:20 PM
NOVN News: Current Report Filing (8-k) 11/29/2016 07:25:38 AM
NOVN News: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206 11/29/2016 06:05:00 AM
News News Alert: New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product 12/05/2016 01:15:32 AM
#16   NOVAN Inc. Not Noven! focus2011 09/30/16 10:12:55 AM
#15   Nice volume VERITAS77 07/14/09 02:56:59 PM
#14   Noven Announces 2008 Second Quarter Financial Results surf1944 08/06/08 09:44:23 AM
#13   8:35AM Noven Pharma announces triggering of $25 mln surf1944 08/04/08 09:19:34 AM
#12   Noven Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript surf1944 06/05/08 02:56:48 PM
#11   CORRECTING and REPLACING Noven Announces First Quarter 2008 surf1944 05/09/08 09:57:39 AM
#10   13-Mar-08 NOVN surf1944 03/13/08 10:08:39 AM
#9   Noven Pharma Gets FDA Warning Letter surf1944 01/10/08 11:18:01 AM
#8   Noven Shares Rise on 3Q Results surf1944 11/10/07 01:06:25 PM
#7   FDA Issues Approvable Letter for Stavzor(TM) Delayed Release surf1944 10/23/07 07:21:11 PM
#6   Oversold with an Improving RSI (NOVN) surf1944 10/11/07 09:07:05 PM
#5   UPDATE 1-RESEARCH ALERT-Raymond James raises Noven to Strong surf1944 10/11/07 11:30:21 AM
#2   Strong Volume Decliners (NOVN) surf1944 10/08/07 09:32:26 PM
#1   Noven Announces Results of Phase 3 Clinical Study surf1944 10/08/07 09:44:04 AM